Evidence mapPaperPMID 32668195Full record

ReviewCell metabolism2020

Mitochondrial Metabolism as a Target for Cancer Therapy.

Karthik Vasan, Marie Werner, Navdeep S Chandel

Abstract readReview
In one paragraph

Review in Cell metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 426 papers.

0numbers the graph read from it
0cells of the map it votes in
426citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

426 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. TargetingJournal for immunotherapy of cancer · 2026
    Article
  20. Article

366 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Karthik VasanDepartment of Medicine, Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Marie WernerDepartment of Medicine, Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Navdeep S ChandelDepartment of Medicine, Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address: nav@northwestern.edu.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008152 · NORTHWESTERN UNIVERSITY · 1987 to 2005
$4.9M
Medical Scientist Training ProgramT32GM144295 · NIGMS · NORTHWESTERN UNIVERSITY · 2022 to 2025
$3.6M
CARCINOGENESIS TRAINING PROGRAMT32CA009560 · NORTHWESTERN UNIVERSITY · 1986 to 2025
$2.2M
NCI NIH HHS F30 CA250236NCI NIH HHS R35 CA197532NCI NIH HHS T32 CA009560NIGMS NIH HHS T32 GM008152NIGMS NIH HHS T32 GM144295
6 · The paper itself

Abstract

Recent evidence in humans and mice supports the notion that mitochondrial metabolism is active and necessary for tumor growth. Mitochondrial metabolism supports tumor anabolism by providing key metabolites for macromolecule synthesis and generating oncometabolites to maintain the cancer phenotype. Moreover, there are multiple clinical trials testing the efficacy of inhibiting mitochondrial metabolism as a new cancer therapeutic treatment. In this review, we discuss the rationale of using these anti-cancer agents in clinical trials and highlight how to effectively utilize them in different tumor contexts.

Indexed as

AnimalsAntineoplastic AgentsHumansMitochondriaNeoplasmsAntineoplastic Agentsmetforminmitochondria

Identifiers

PMID32668195
PMCPMC7483781

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.